Adaptive Randomization of Neratinib in Early Breast Cancer

Affiliations

Comment

Marc Buyse et al. N Engl J Med. 2016.

. 2016 Oct 20;375(16):1591-2.

doi: 10.1056/NEJMc1609993.

¹ International Drug Development Institute, Louvain-la-Neuve, Belgium marc.buyse@iddi.com.

No abstract available

Comment in

Adaptive Randomization of Neratinib in Early Breast Cancer.
Berry D, Esserman L. Berry D, et al. N Engl J Med. 2016 Oct 20;375(16):1592-3. doi: 10.1056/NEJMc1609993. N Engl J Med. 2016. PMID: 27797314 No abstract available.
Adaptive Randomization of Neratinib in Early Breast Cancer.
Harrington D, Parmigiani G. Harrington D, et al. N Engl J Med. 2016 Oct 20;375(16):1593-4. doi: 10.1056/NEJMc1609993. N Engl J Med. 2016. PMID: 28103002 No abstract available.

I-SPY 2--A Glimpse of the Future of Phase 2 Drug Development?
Harrington D, Parmigiani G. Harrington D, et al. N Engl J Med. 2016 Jul 7;375(1):7-9. doi: 10.1056/NEJMp1602256. N Engl J Med. 2016. PMID: 27406345 No abstract available.